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An Anti-ICAM-2 (CD102) Monoclonal Antibody Induces Immune-mediated
Regressions of Transplanted ICAM-2-negative Colon Carcinomas1
Ignacio Melero,2 Izaskun Gabari, Angel L. Corbı´, Miguel Relloso, Guillermo Mazzolini, Volker Schmitz,
Mercedes Rodriguez-Calvillo, In˜igo Tirapu, Emilio Camafeita, Juan P. Albar, and Jesu´s Prieto
Gene Therapy Unit, Department of Medicine, University of Navarra School of Medicine, 31008 Pamplona [I. M., I. G., G. M., V. S., M. R-C., I. T., J. P.]; Proteomics Facility and
Department of Immunology and Oncology, Centro Nacional de Biotecnologı´a (Pharmacia/ Consejo Superior de Investigaciones Cientificas), Canto Blanco, E-28049 Madrid
[E. C., J. P. A.]; and Centro de Investigaciones Biolo´gicas, Consejo Superior de Investigaciones Cientificas, 28006 Madrid [A. L. C., M. R.] Spain
ABSTRACT
Monoclonal antibodies (mAbs) can mediate antitumor effects by indi-
rect mechanisms involving antiangiogenesis and up-regulation of the cel-
lular immune response rather than by direct tumor cell destruction. From
mAbs raised by immunization of rats with transformed murine endothe-
lial cells, a mAb (EOL4G8) was selected for its ability to eradicate a
fraction of established colon carcinomas that did not express the
EOL4G8-recognized antigen. The antigen was found to be ICAM-2
(CD102). Antitumor effects of EOL4G8, which required a functional
T-cell compartment, were abrogated by depletion of CD8 cells and
correlated with antitumor CTL activity, whereas only a mild inhibition of
angiogenesis was observed. Interestingly, we found that EOL4G8 acting
on endothelial ICAM-2 markedly enhances leukotactic factor activity-1-
independent adhesion of immature dendritic cells to endothelium—an
effect that is at least in part mediated by DC-SIGN (CD209).
INTRODUCTION
mAbs3 have been used to inflict selective damage to malignant cells
in vivo both in animal experimentation and at the clinic (1). More
recently, mAbs have been used to elicit indirect mechanisms that
efficiently treat tumors by potentiating the immune response (2–4) or
by decreasing angiogenesis in the malignant tissue (5, 6).
To identify novel antibody specificities that could operate through
these indirect mechanisms, we immunized rats with mouse endothe-
lioma cells and searched for mAbs displaying antitumor effects in
vivo. We found one antibody fulfilling such features that recognized
the adhesion molecule ICAM-2 (CD102). This surface antigen is a
glycoprotein that belongs to the Ig superfamily encompassing two Ig
domains (7–9). It was functionally identified in humans as a counter-
receptor for the leukocyte integrin LFA-1 (8). Tissue distribution for
ICAM-2 in humans includes constitutive expression on endothelial
cells as well as on T and B lymphocytes (7). Recently a second
counter-receptor for ICAM-2 has been identified selectively ex-
pressed on human DCs, and that molecule is the C-type lectin named
DC-SIGN (CD209; Refs. 10–13). DC-SIGN was originally described
as a selective ligand for ICAM-3 (12), but recently its binding to
ICAM-2 was found to be stronger, and it has been shown to be
involved in the traffic of DCs to tissues (10). Mannose-containing
moieties attached on ICAMs are involved in the binding to DC-SIGN
(14). Besides its proposed role in cell traffic, DC-SIGN is important
at the immunological synapse that is formed by T cells and antigen-
presenting DCs (13, 15). A number of DC-SIGN murine homologues
have been identified recently, but information on its function is not
available yet, although one of the homologues is expressed in DCs at
the RNA level (16). ICAM-2/ mice develop normal immune re-
sponses and accordingly the function of this molecule is largely
dispensable (17), indicating that its function is probably redundant
with other proteins of its family.
This study demonstrates that in vivo treatment with anti-ICAM-2
mAb can cure established transplanted colon carcinomas that are
completely ICAM-2-negative through mechanisms that are dependent
on the induction of tumor-specific CTL-mediated immune responses.
Evidence has been obtained that ICAM-2 bound by EOL4G8 up-
regulates its adhesiveness to DC-SIGN, providing a mechanistic ra-
tionale to the enhancement of antitumor immunity.
MATERIALS AND METHODS
Cell Lines, Antibodies, and Reagents. MC38 and CT26 have been de-
scribed previously (18). PY-4.1 and H5V are SV40 T-transformed endotheli-
omas (19, 20) generously given by V. Bautch (University of North Carolina,
Chapel Hill, NC) and A. Mantovani (Instituto Mario Negri, Milan, Italy).
These cells have been derived from transgenic mice ubiquitously expressing
SV40 T antigen. D2SC/1 is a spleen-derived murine DC line (kindly provided
by P. Ricciardi-Castagnoli, University of Milan, Italy; Refs. 21, 22). Human
DC-SIGN-expressing transfectants in K562 cells and the anti DC-SIGN mAb
(MR-1) have been described (23). 3C8 antimouse ICAM-2 was from PharM-
ingen (Heidelberg, Germany) as well as anti-ICAM-1, anti-VCAM-1, anti
H-2Ld, anti H-2Kb, anti-CD3 anti-CD28, anti-LFA-1, anti-CD31, and second-
ary FITC-tagged antirat IgG and IgG2b antibodies. Hybridoma production and
purification of EOL4G8 mAb was as described (24). The screening was
performed by selecting out antibodies binding PY4–1 but not various carci-
noma cell lines. Hybridomas fulfilling both criteria were grown as ascites in
BALB/c-nu/nu mice, and ascites fluid was tested for in vivo interference of
CT26-derived tumors implanted in syngeneic mice by giving it inside tumor
nodules. Anti-CD8-depleting antibody was ascitic fluid of the hybridoma
H35–17.2 (American Type Culture Collection; Ref. 25). TS2.18 antihuman
CD18 was from Francisco Sanchez-Madrid (Hospital de la Princesa, Spain).
Antibody-conjugated magnetic beads and cell separation protocols were from
Miltenyi (Bergisch Gladbach, Germany). Rat IgG, Colchicine, ConA, and
EGTA were from Sigma (Madrid, Spain). Culture medium and FCS were from
Life Technologies, Inc. (Cergy-Pontoise, France).
Flow Cytometry and Immunohistochemistry. Indirect and direct immu-
nofluorescence and flow cytometry were performed as described (24) using a
FACScalibur (Becton Dickinson, Mountain View, CA). Cryosections were
prepared and processed for indirect immunohistochemical staining as de-
scribed (24).
Immunoprecipitation and Western Blot. PY4.1 cells were surface bio-
tinylated with sulfo-NHS-Biotin (Pierce, Rockford, IL), lysed, and immuno-
precipitates were obtained as described (24, 26). Immunoprecipitates were
analyzed by SDS-PAGE, transferred onto a polyvinylidene difluoride mem-
brane (Immobilon-P; Millipore, Bedford, MA), and developed with streptavi-
din-peroxidase (Streptavidin-HPR; Pierce) and chemiluminescence (ECL;
Amersham-Pharmacia, Barcelona, Spain; Ref. 24). Western blotting with
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EOL4G8 was performed as described (25) with ascites 1/1000 or 5 g/ml of
purified mAb in blocking solution.
Affinity Chromatography, SDS-PAGE, and In-Gel Digestion of Pro-
teins. Purified EOL4G8 was covalently bound to Sepharose beads (CNBr-
activated Sepharose; Amersham-Pharmacia-Biotech) according to the manu-
facturer’s protocols. Columns were packaged in 2-ml syringes and, after
conditioning with extensive washing with PBS, were loaded with PY-4.1 cell
lysate from 108 cells in PBS with 1% Triton Tx-100 containing phenylmeth-
ylsulfonyl fluoride, aprotinin, and leupeptin (Sigma). Optimal elution buffer
was 1 M Tris (pH 12), and 0.5-ml fractions were collected. Concentrated
fractions (Centricon; Millipore, Madrid, Spain) were run in 12% SDS-PAGE,
and stained protein bands were excised from the gel and then processed
automatically using an Investigator ProGest protein digestion station (Genomic
Solutions, Cambridgeshire, United Kingdom). Peptides were eluted with ace-
tonitrile, 25 mM ammonium bicarbonate, and 10% formic acid (v/v) for a final
extraction volume of 100 l.
MALDI Peptide Mass Fingerprinting, Database Searching, and PSD
MALDI Analysis. A 0.5-l aliquot of the extraction solution was used to
measure automatically the mass fingerprint on a Bruker Reflex III MALDI-
time of flight mass spectrometer (Bruker-Franzen Analytic GmbH, Bremen,
Germany) in positive ion reflector mode using delayed extraction. The meas-
ured tryptic peptide masses were transferred automatically through the MS
BioTools program as inputs to search automatically the National Center for
Biotechnology Information database using Mascot software (Matrix Science,
London, United Kingdom). The PSD MALDI spectrum was recorded auto-
matically, and the precursor ion was selected by FAST deflecting pulses. Data
analysis was performed using Bruker BioTools 2.0 software.
Mice and in Vivo Experimentation. Female C57BL/6, BALB/c, and
BALB/c-nu/nu mice (6–12-weeks old) were purchased from Jackson (Barce-
lona, Spain). A breeding pair of Rag2/ mice was obtained from T. Rolink
(Basel Institute for Immunology, Basel, Switzerland; Ref. 27) and bred in our
animal facility. s.c. tumors were obtained by injection of 5  105 CT26 cells
into BALB/c mice, 1  105 MC38 in C57BL/6 mice (18), or 1  106 PY4.1
cells in BALB/c-nu/nu mice (19), and monitored as described (25). s.c.
Matrigel plugs were implanted by injection of ice-cold Matrigel containing 10
ng/ml VEGF and 10 ng/ml bFGF (Peprotech, London, United Kingdom). Ten
days later, plugs and surrounding tissue were paraffin-embedded and H&E
stained. Endothelial cells with lumen per microscopic field (200) were
counted in at least 5 fields/section and 5 sections/Matrigel plug (identity of
endothelium was confirmed by immunohistochemistry with anti-Von Will-
ebrand factor in serial sections; Refs. 25, 28, 29).
CTL Studies and ELISAs. Standard 51Cr release were done on CT26 and
P815 cells as target cells using spleen cells restimulated in vitro with Mytomi-
cin-C-treated CT26 cells at a 10:1 ratio as described (25, 30).
Adhesion Experiments. Human monocyte-derived DCs and mouse bone
marrow-derived DCs were obtained as described (18, 31). PY-4.1 cells were
seeded in flat-bottomed 96-well-plates and cultured in DMEM 10% FCS until
confluence was reached. Then FCS was washed, and mAbs and 8  104 DCs
in serum-free DMEM were added and incubated for 90 min under rotation at
60 rpm. Wells were subsequently washed five times with prewarmed DMEM,
and attached DCs were counted under phase contrast microscopy in defined
surfaces with a grid. Four equally placed surfaces were counted per well by an
operator blinded to the experiment.
RESULTS
Obtainment, Selection, and Characterization of the EOL4G8
mAb. To obtain mAbs, rats were immunized with mouse endothe-
lial cells derived from hemangiomas raised in SV40T-transgenic
mice (19, 20). A primary screening was set up to search for
antibodies that could bind surface proteins on murine endothelioma
cells but not on a wide panel of cell lines of epithelial origin. Thus,
selected antibodies were screened for in vivo antitumoral effects.
The antibody produced by the hybridoma EOL4G8 (rat IgG2b)
fulfilled both criteria. As it can be seen in Fig. 1, a and b, EOL4G8
brightly stained the cell surface of two endothelioma cell lines that
coexpressed endothelial lineage and activation markers such as
CD31, CD34, the v3 integrin, ICAM-1, ICAM-2, and VCAM-1.
By contrast as shown in Fig. 1, c and d, EOL4G8 completely failed
to detect antigens on the surface of the colon carcinoma cell lines
CT26 and MC38 that were MHC class I-positive. EOL4G8 immu-
noprecipitated a single band of 59 kDa (Fig. 1e) on reducing and
nonreducing conditions from lysates that had been obtained from
the endothelioma cell line PY-4.1.
Immunohistochemical analysis of BALB/c livers harboring CT26-
derived experimental metastasis showed a pattern of stromal staining
Fig. 1. EOL4G8 mAb recognizes a 59 kDa surface protein on murine endotheliomas
and stains vessels in the stroma of experimental colon cancer liver metastasis. a and b,
indirect immunofluorescence analyzed by FACS of the expression of the antigen recog-
nized by EOL4G8 mAb, and the indicated surface antigens on the PY-4.1 endothelioma
cell line (a) and the H5V endothelioma cell line (b). c and d, lack of detectable expression
by FACS of the antigen recognized by EOL4G8 on the colon carcinoma cell lines CT26
(c) and MC38 (d). e, 10% SDS-PAGE analysis of immunoprecipitates obtained with
EOL4G8 from lysates of PY-4.1 cells in which surface proteins had been labeled with
biotin. f–h, microscopic fields at different magnifications (100, 200, and 400) of
immunohistochemical staining with EOL4G8 mAb of liver metastasis of CT26 (i).
Representative field (200) of an immunohistochemical staining with EOL4G8 mAb of
cryosections from skeletal muscle (diaphragm) from normal BALB/c mouse. j–l, indirect
immunofluorescence staining of PY-4.1 with EOL4G8 mAb at 4°C (j) after an incubation
for 25 min at 37°C (k) and after 1 h at 37°C (l). Images of UV-light microscopy are
representative of at least five experiments with observation of multiple microscopic fields.
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in vascular structures with lumen (Fig. 1, f–h). Positive cells were
confirmed to be endothelial by positive immunostaining of serial
sections with anti-CD31 mAb (not shown). It should be noted that the
number of EOL4G8 cells in tumor stroma was outnumbered by at
least 3-fold by CD31 cells, indicating that not every endothelial cell
in the malignant tissue was EOL4G8 (not shown). Interestingly,
these immunohistochemical analyses did not detect any cells of
healthy liver including sinusoidal and nonsinusoidal vascular struc-
tures. Positive staining with EOL4G8 mAb was also found in many
vascular structures within skeletal muscle (Fig. 1i), whereas only a
Fig. 2. EOL4G8 mAb recognizes murine ICAM-2 (CD102). a, MALDI fingerprinting analysis of the band in fraction 2 (visualized in the figure by Western blot with EOL4G8 mAb
and marked with a dotted arrow), as it was obtained from PY-4.1 lysates using affinity chromatography columns packaged with Sepharose covalently linked to EOL4G8 mAb and
analyzed subsequently by SDS-PAGE. Scores obtained on computer assisted comparison of the molecular masses of the tryptic peptides with those present in the National Center for
Biotechnology Information database are summarized in the table included. b, 12% SDS-PAGE of immunoprecipitates obtained with commercial 3C8 anti-ICAM-2 mAb, anti MECA-32
mAb (negative control), or with EOL4G8 mAb that were developed in Western blot by EOL4G8 mAb. c, PSD MALDI analysis of the peak indicated by the arrow in a, which yields
a fragment ion spectrum compatible with the sequence (detailed in the figure) proposed for that peak.
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minority of vascular structures (mainly arteriolas) were detected in
brain, eye, testis, heart, and lung tissue (not shown).
On PY-4.1 cells the antigen recognized by EOL4G8 evenly deco-
rated the plasma membrane on indirect immunofluorescence staining
(Fig. 1j), but it underwent capping at 37°C for 20 min (Fig. 1k) and
internalization at later time points (Fig. 1l).
Affinity chromatography with EOL4G8 mAb purified the mem-
brane protein from PY-4.1-derived cell lysates. Elution fractions
could be followed by Western blot with EOL4G8. Fraction F2 (indi-
cated with a dotted arrow in Fig. 2a) was concentrated, run in
SDS-PAGE, and the excised band was subjected to tryptic peptide
fingerprinting analysis by MALDI. The database search using tryptic
peptide masses observed in the MALDI peptide fingerprinting (Fig.
2a) proposed the intercellular adhesion protein- 2 from mouse as a
top candidate as shown in the score table under Fig. 2a.
Furthermore, immunoprecipitates obtained with a commercial an-
timouse ICAM-2 mAb (3C8; Ref. 9) were recognized in Western blot
analysis by EOL4G8 mAb depicting a band with identical electro-
phoretic mobility to that immunoprecipitated by EOL4G8 itself (Fig.
2b). Identification was additionally confirmed by MALDI-PSD anal-
ysis. Fig. 2c shows a recorded series of y-, a- and b-type fragment
ions generated by decomposition of the peptide at m/z  1194.64
(peak) in the mass fingerprinting spectrum, which are compatible with
its putative sequence. Molecular weight of 31.8 kDa from the pre-
dicted peptide backbone indicates heavy glycosylation if compared
with the estimated 59 kDa in SDS-PAGE analysis of immunoprecipi-
tates.
Antitumor Effects of EOL4G8 anti-ICAM-2 mAb. Experiments
shown in Table 1 demonstrate that in vivo administration of EOL4G8
mAb to mice bearing established s.c. tumors derived from the injec-
tion of CT26 or MC38 cells resulted in complete regressions in an
important fraction of cases. In this series of experiments the antibody
was given either as ascites fluid or as purified protein. Three doses
repeated every third day of 100 l of ascites or 150 g of purified
antibody were chosen. In the first two experiments EOL4G8 was
injected inside the malignant nodule in an attempt to reach high local
concentrations in the tumor environment. Treatment of CT26 tumors
was started on day 7 or 8 after tumor inoculation when tumor nodules
rank from 4 to 7 mm (mean diameter). Injection of purified EOL4G8
mAb through i.p. route at similar doses and dosing schedule induced
complete regressions in a comparable fraction of tumors, indicating
that the intratumoral route was not required. All of the tumor regres-
sions were sustained during at least 6 months without obvious signs of
tumor relapses or toxicity related to treatment.
Similar experiments were undertaken with MC38-derived tumors.
In this case the effects were not curative if the onset of the i.p. regime
of EOL4G8 mAb was postponed until day 7. However, two tumors of
six cases completely regressed if the treatment course started on day
5. Moreover, when i.p. treatment immediately followed MC38 tumor
cell inoculation, three cases of four mice underwent complete regres-
sion after transient detectable tumor growth.
Surprisingly, no antitumor activity against CT26 s.c. tumors was
detected in immunodeficient BALB/c-nu/nu or Rag2/ mice (in
BALB/c background) suggesting a role of the immune system in the
observed phenomenon.
Mechanisms Involved in EOL4G8 Antitumor Activity. Ad-
dressing this immune system involvement, we found that weekly
depletion of CD8 cells with specific mAbs eliminated the antitumor
effects of EOL4G8 (Fig. 3, a and b). Depletion of CD4 cells in a
similar type of experiment did not exert a significant effect on the
outcome of EOL4G8 mAb treatment (not shown). In accordance, we
found in two experiments that 20 days after EOL4G8 treatment the
spleen of mice bearing CT26 s.c. tumors had specific antitumor CTL
activity (Fig. 3c) that was not detected in mice treated with control
antibody. Furthermore, tumors 7 days after treatment showed a prom-
inent infiltrate of mononuclear cells (especially around vessels) also
with some granulocytes, including eosinophils and areas of tumor
necrosis (Fig. 3d).
Resting murine T lymphocytes expressed barely detectable levels
of ICAM-2 but concanavalin  interleukin 2 stimulated T lympho-
blasts readily expressed this molecule with high intensity (Fig. 3e, f).
Therefore, a potential way of action of the antibody was to provide
costimulatory signals to activated ICAM-2 antitumor T cells. None-
theless we could not demonstrate any activity of EOL4G8 mAb to
provide costimulation to suboptimal stimulation with anti-CD3 anti-
bodies in vitro either to induce proliferation or IFN- secretion,
regardless of the extensive series of experimental conditions under
which anti-CD28 used as a positive control readily costimulated these
effects (not shown). Those conditions included rested T-cell blasts
that intensely expressed ICAM-2 and mixed lymphocyte culture-type
cultures of T cells and fully allogeneic DCs. In both cases EOL4G8
mAb, either attached to plastic or in soluble form, failed to modify the
response to suboptimal anti-CD3 mAb or alloantigens.
We carried out experiments to assess a potential antiangiogenic
effect of this antibody although the antitumor activity could not be
explained solely by antiangiogenesis because it was not found in
immunodeficient mice. The subject was studied by implanting Matri-
gel plugs embedded in VEGF bFGF in nude mice and assessing the
number of endothelial cells in microscopic fields within the Matrigel
plug. An inhibition ( 30%) induced by EOL4G8 mAb was found in
comparison with mice treated with control antibodies (Fig. 3g). Fur-
thermore, EOL4G8 was able to decrease the rate of progression of
PY-4.1-derived hemangiomas in nude mice indicating the ability of
the antibody to interfere in vivo with the growth of these ICAM-2-
transformed endothelial cells (Fig. 3h).
EOL4G8 mAb Provokes Attachment of DCs to ICAM-2 En-
dothelial Cells. Incubation of PY-4.1 cells in vitro with EOL4G8 did
not result in changes in cell viability, morphology, proliferation, or
tubulization on Matrigel. However, we found that preincubation of a
monolayer of PY-4.1 with EOL4G8 induced the adhesion to it of a DC
line (D2SC/1) that represents DCs at an immature status (Ref. 21; Fig.
4a). This effect was not observed with control antibodies including a
commercially available antimurine ICAM-2 antibody (3C8). The in-
creased adhesion was not blocked by an anti-LFA-1 mAb that inhibits
Table 1 Antitumor effects of treatment of established s.c. tumors with EOL-4G8 mAba
Tumor/strain Route/days mAb form
Treatment
Saline EOL4G8 IgG
CT26/BALB/c i.t.b 7, 10, 12 Ascitesc 0/4 3/4 ND
i.t. 8, 10, 13 purificated 0/4 4/4 1/4
i.p. 8, 10, 12 purificate 0/3 5/6 0/4
i.p. 7, 10, 12 purificate ND 4/6 0/6
MC38/C57BL/6 i.p. 0, 3, 7, 10 purificate 0/4 3/4 0/4
i.p. 5, 8, 11 purificate 0/6 2/6 0/7
i.t. 7, 9, 11, 18 purificate 0/5 0/5 0/5
CT26 BALB/c-nu/nu i.p. 0, 3, 7, 10 Ascites 0/2 0/4 ND
i.p. 5, 8, 11 purificate 0/4 0/4 ND
CT26 BALB/c Rag 2/ i.p. 0, 3, 7, 10 purificate 0/6 0/6 ND
a Fraction of tumor-free surviving mice (number of cured mice/total number of mice)
in different experiments 24 weeks after being injected s.c. in the right flank with the
indicated tumor cell lines to develop tumor nodules. Mice were treated with the indicated
antibody doses, via the indicated routes, on the indicated days after tumor inoculation. In
some cases mice received an equivalent volume of saline buffer or polyclonal rat IgG as
a control. Mice were terminated when tumor nodules surpassed 24 mm (mean diameter)
or were followed up for 6 months if disease-free.
b i.t., intratumor; i.p., intraperitoneal; ND, not done.
c Ascites fluid drained from peritoneal cavity of athymic nude mice injected i.p. with
the EOL4G8 hybridoma; 100 l were given per dose.
d Purified antibody obtained with protein G Sepharose columns from ascites fluid that
was given at 150 g/dose.
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its binding to ICAM-1 and remained unaffected by an antibody that
also binds a surface molecule of endothelial cells (anti-MECA-32).
The augment of cell adhesion took place at 4°C and when soluble
nonattached mAb had been removed indicating that this phenomenon
did not require active metabolism nor direct access of soluble anti-
body to the DC line (Fig. 4a). Furthermore, EOL4G8 mAb was able
to promote adhesion of DCs to affinity-purified PY-4.1-derived
ICAM-2, showing that enhancement of adhesion took place irrespec-
tive on whether ICAM-2 was or was not attached to a cell surface
(Fig. 4b). D2SC/1 also expresses low levels of ICAM-2 and, there-
fore, EOL4G8 could be acting on the DC side. (Fig. 4c). EOL4G8-
increased adhesion is dependent on divalent cations because it is
inhibited by EGTA (Fig. 4d) and is dependent on the tubulin cytoskel-
eton of DCs as deduced from inhibitions observed with colchicine
(Fig. 4d). Enhancement of adhesion by EOL4G8 also took place with
cultured bone marrow-derived murine DCs thus excluding artifacts
because of the transformed phenotype of the D2SC/1 cell line
(Fig. 4e).
EOL4G8 mAb Enhances Adhesion of Human DCs to Mouse
Endothelium in a DC-SIGN-mediated Fashion. EOL4G8 also in-
creases the adhesion of human DCs to the murine endothelioma
PY-4.1 (Fig. 5a), although the antibody does not bind human ICAM-2
nor does it stain human DCs (FACS histogram in Fig. 5a). Therefore,
the antibody in this case cannot bind both cell surfaces to form a
bridge between them. Instead the mechanism seems to be that
EOL4G8 binding modifies ICAM-2 in such a way that it becomes
more prone to interact with a putative ligand on human DCs that are
not LFA-1, as deducted from the lack of inhibition observed with an
anti-CD18 mAb that blocks LFA-1-dependent adhesion (Fig. 5b). As
shown in Fig. 5b, an anti-DC-SIGN mAb (MR-1) (23) inhibits 40–
50% of the EOL4G8-induced adhesion of human DCs to mouse
PY-4.1 endothelioma cells. To additionally confirm the involvement
of DC-SIGN, a series of experiments was carried out with transfec-
tants in human K562 cells, which stably expressed DC-SIGN (FACS
histogram under Figs. 5, c and d) or in equivalent untransfected cells.
As it can be seen in Fig. 5c, EOL4G8 mAb intensely promoted the
adhesion of the DC-SIGN transfectant to PY-4.1 cells, whereas it did
not modify the adhesion of the untransfected K562 cells (Fig. 5d).
Moreover the mAb against DC-SIGN inhibited60% of the adhesion
of DC-SIGN K562 to mouse endothelium. All of these results
strongly indicate that EOL4G8 enhances tumor immunity by promot-
ing the adhesion of ICAM-2 cells to DC-SIGN molecules expressed
on DCs.
DISCUSSION
This study shows that in vivo injection of a mAb that recognizes
ICAM-2 (CD102) eradicates experimental solid tumors that do not
Fig. 3. Treatment with EOL4G8 mAb stimulates
antitumor CTL-mediated immune responses and
can interfere with endothelial cells in vivo. a, fol-
low-up of tumor mean diameters of CT26 tumors in
mice receiving 150 g i.p of EOL 4G8 mAb on
days 7, 10, and 12 after tumor inoculation. b, sim-
ilar to a, but in this case mice received 100 l of
ascites containing depleting anti-CD8 mAb on days
6, 14, and 21 after tumor inoculation. c, CTL ac-
tivity against CT26 in 4-hour 51Cr release assays of
splenocytes obtained from mice bearing s.c. CT26
tumors treated on days 7, 10, and 12 with 150 g of
EOL4G8 or control rat IgG. Results from two in-
dependent experiments with two mice/group are
shown. Specificity was checked by lack of cytoly-
sis of P815 cells in experiments performed in par-
allel (not shown). d, H&E staining of sections ob-
tained from a representative s.c. CT26 tumor taken
14 days after tumor cell inoculation once mice had
received treatment with two doses of 150 g of
EOL4G8 mAb given on days 6 and 8. A (100)
magnification field is shown with a detail (200)
shown in the top right corner of the picture. Eo-
sinophils are indicated by the arrows. e and f,
expression of ICAM-2 as detected by EOL4G8 and
FACS analysis in magnetic bead-purified T cells
from normal resting BALB/c spleens containing
29% CD8 cells and 60% CD4 cells (e) and in
those lymphocytes after activation with 2 g/ml of
ConA plus 500 IU of human recombinant interleu-
kin 2 for 4 days (f). Results were confirmed with
the 3C8 anti ICAM-2 mAb (not shown). g, vascu-
larization of Matrigel implants embedded in VEGF
and bFGF placed under the skin of BALB/c nude
mice that received 150 g of EOL4G8 or control
antibody on days 0 and 3 after Matrigel injection,
measured as the number of endothelial cells in
microscopic fields (200) from H&E-stained sec-
tions. Four Matrigel plugs were implanted in each
mouse with a total of seven mice/group, and data
were from five sections from each plug. Statistical
significance was P  0.01 according to Student’s t
test. h, sequential hemangioma growth (assessed by
mean diameter in mm) under the skin of BALB/c
nude mice injected with 106 PY-4.1 cells on day 0
and treated with EOL4G8 mAb or control rat IgG
(150 g/i.p. dose) on days 3, 6, and 9; bars, SD.
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express ICAM-2. Hence, the antibody required the contribution of
endogenous mechanisms to interfere with cancer progression. Inef-
fectiveness of the antibody in nude and rag2/ mice pointed out an
absolute requirement of T cells. Depletion experiments with anti-CD8
mAb clearly showed that CTLs were required for antitumor effects,
and this fact correlated with the detection of antitumor-specific CTL
activity in EOL4G8-treated mice. mAbs that enhance the antitumor
immune response to produce therapeutic immunity have been de-
scribed. The most potent seem to be anti-CTLA-4 (2), anti-4–1BB (3),
and anti-CD40 (4). Each of them acts through different mechanisms
that share the activation of a CTL response against the tumor as the
final effector mechanism.
ICAM-2 is readily expressed on murine activated T cells but
very poorly so on resting T cells. Thus, it was conceivable that
EOL4G8 could be providing costimulatory signals to T cells pre-
activated through the T-cell receptor. However all of our attempts
to show that costimulatory activity for proliferation or cytokine
secretion in vitro have failed. Therefore, it is still unresolved
whether ICAM-2 artificial ligation with EOL4G8 mAb on T cells
would be involved in the observed antitumor effects by direct
signals through ICAM-2. ICAM-2 bound by mAbs has not been
involved yet in active signaling unlike the case of related mole-
cules such as ICAM-1 (32), ICAM-3 (33), and VCAM-1 (34). The
reported intracytoplasmic interactions of ICAM-2 with cytoskel-
etal proteins (35, 36) may be involved in these phenomena, and are
consistent with our observations on the capping and internalization
induced by EOL4G8.
CTL activity and the lymphoid infiltration of tumors after sys-
temic treatment with EOL4G8 speak of an activation of the im-
mune system provoked by the antibody in vivo. The presence of
granulocytes in the infiltrate is also interesting and resembles to
some extent observations in tumors transfected to produce certain
cytokines (37) or fas-L (38, 39). Because CT26 is more immuno-
genic than MC38 (18), the higher efficacy of EOL4G8 treatment
on CT26-derived tumors indicates that EOL4G8 amplifies a weak,
preexisting immune response. The basal immunogenicity of CT26
cells is best indicated by experiments that show a slower growth of
these transplanted tumors in BALB/c mice than in Rag-2/
syngeneic mice.4
4 I. Tirapu et al. submitted for publication.
Fig. 4. EOL4G8 enhances the adhesion of DCs to mouse
endothelial cells expressing ICAM-2. a, adhesion of
D2SC/1 dendritic immortalized cell line to confluent mono-
layers of PY-4.1 cells assessed by counting DC cells/mm2
under phase contrast microscopy after washing unbound
cells. Results are mean of four counts of equally placed
fields inside triplicate wells. Indicated antibodies were used
at a concentration 5 g/ml and added during the assay (top
panels) or preincubated during 1 h at 4°C and then washed
three times before addition of D2SC/1 cells (bottom panel;
b) Adhesion to PY-4.1 cells assessed as in a to wells coated
with 2 g/ml of purified ICAM-2 protein from fraction 3
(F3) in Fig. 2a. c, FACS analysis of the expression of
ICAM-2 on D2SC/1 cells (isotype matched negative con-
trol in a shaded histogram; d, adhesion experiments as in a
but in which the indicated concentrations of colchicine or
EGTA were included during the assays. e, adhesion exper-
iments to monolayers of PY4.1 cells performed similarly to
those in a and d but in which mouse bone marrow-derived
DCs were used instead of D2SC/1 cells; bars, SD.
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Carbohydrates attached to ICAM-2 are ligands of the DC-SIGN
lectin (10). DC-SIGN on interaction with ICAM-3 has been found
instrumental for the early low avidity interactions of DCs and T cells
(12). Our results show an enhanced attachment of immature DCs to
endothelial cells on incubation with EOL4G8. Because EOL4G8
stains with some degree of selectivity tumor endothelium, it is pos-
sible that the mAb favors recruitment of DCs into malignant tissue.
Besides it is tempting to speculate that the antibody would modify
ICAM-2/DC-SIGN interactions at the immunological synapse be-
tween lymphocytes and DCs. Our data with the interspecies adhesion
systems, involving human DCs and mouse endothelial cells, strongly
suggest that EOL4G8 operates increasing the adhesion of ICAM-2 to
DC-SIGN. The involvement of human DC-SIGN is shown both by
antibody blocking and by transmission of the activity on transfection
of the DC-SIGN-encoding cDNA. Definitive proof of such hypothe-
ses awaits additional characterization on the function of mouse ho-
mologues of DC-SIGN (16).
EOL4G8 binds ICAM-2 at an epitope that interferes with LFA-1
binding (an activity that maps to the NH2-terminal Ig domain of
ICAM-2; Refs. 7, 8, 13) but which could up-regulate somehow the
binding to DC-SIGN (an activity dependent on the COOH-terminal Ig
domain of human ICAM-2 and its attached carbohydrates; Ref. 13).
Peculiar functional properties of the epitope bound by EOL4G8 mAb
might be crucial to understand its biological properties. This is sup-
ported by our observation that another antibody against ICAM-2
(3C8), which also interferes with adhesion to LFA-1 (Ref. 9; although
it binds to a noncompeting epitope), fails to up-regulate DC adhesion
to endothelium. A conformational change induced by EOL4G8 in the
protein backbone of ICAM-2 or its attached carbohydrates, enhancing
its adhesiveness to DC-SIGN, could be the intimate mechanism of
action. This is our best-fitting explanation to the observation that
EOL4G8 also enhances binding of DCs to immunopurified ICAM-2
attached to plastic. We cannot exclude that other putative ICAM-2-
binding lectins might also be involved.
EOL4G8 inhibits angiogenesis of Matrigel implants, but such an
effect, although detectable, was very weak in comparison to inhibi-
tions reported for other agents of which the efficacy is entirely
dependent on this mechanism (28, 29, 40). An appraisal of the real
extent of the contribution of antiangiogenesis to the overall EOL4G8
efficacy is difficult, but this mechanism is not sufficient to cause
macroscopic antitumor activity in immunodeficient mice.
As a whole our studies define ICAM-2 as a new target for anti-
bodies mediating antitumor effects through indirect mechanisms that
seem to include enhancement of the intrinsic adhesion properties of
Fig. 5. EOL4G8 augments the adhesion of human
DCs and of a human transfected cell line expressing
DC-SIGN to mouse endothelium. a, adhesion experi-
ments to monolayers of PY-4.1 murine endothelial cell
line similarly performed to those in Fig. 4 but in which
human monocyte-derived DCs were used instead of
DCs of murine origin. Lack of staining of these human
DCs with the antimurine ICAM-2 mAbs EOL4G8 and
3C8 is shown in the FACS histogram within the panel.
b, inhibition of EOL4G8 induced adhesion of human
DCs to PY4.1 cells as detected on incubation with the
indicated mAbs. c, adhesion of K562 cells transfected
to stably express DC-SIGN onto a confluent monolayer
of PY-4.1 cells in the presence of the indicated anti-
bodies. d, adhesion experiments identically performed
as in c but with untransfected control K562 cells. FACS
analysis of the levels of expression of DC-SIGN on
staining with a specific mAb (MR-1) are shown within
c and d; bars, SD.
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this molecule. In vivo, the injected antibody finds its cognate antigen
mainly on activated T cells and on endothelial cells, and is subse-
quently capable to ignite antitumor immune mechanisms that can
eradicate established tumors.
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